3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other solid neoplasm
1
Conditions
Breast Neoplasms
11
Prostatic Neoplasms
7
Neoplasm Metastasis
5
Ovarian Neoplasms
4
Neoplasms
4
Triple Negative Breast Neoplasms
3
Endometrial Neoplasms
3
Small Cell Lung Carcinoma
2
Fallopian Tube Neoplasms
2
mCRPC
1
Wilms Tumor
1
Vaginal Neoplasms
1
Uterine Cervical Neoplasms
1
Stomach Neoplasms
1
Sarcoma, Ewing
1
Sarcoma
1
Rhabdomyosarcoma
1
Rhabdoid Tumor
1
Recurrence
1
Pheochromocytoma
1
Pathologic Complete Response
1
Paraganglioma
1
Pancreatic Neoplasms
1
Osteosarcoma
1
Neuroectodermal Tumors, Primitive, Peripheral
1
Neuroblastoma
1
Multiple Myeloma
1
Lymphoma, Non-Hodgkin
1
Lung Neoplasms
1
Leukemia, Myeloid, Acute
1
Interventions
Injections
13
pembrolizumab
10
tislelizumab
9
toripalimab
6
atezolizumab
4
Nivolumab
4
Carboplatin
3
trastuzumab deruxtecan
2
olaparib
2
lenvatinib
2
Pemetrexed
2
Paclitaxel
2
Oxaliplatin
2
Gemcitabine
2
Fluorouracil
2
Docetaxel
2
Cyclophosphamide
2
Cisplatin
2
Cetuximab
2
Bevacizumab
2
zimberelimab
1
talazoparib
1
spartalizumab
1
sotorasib
1
serabelisib
1
penpulimab
1
niraparib
1
nedaplatin
1
mirdametinib
1
fludarabine phosphate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Advanced Solid Tumor
×
talazoparib
×
1 year
×
Clear all
NCT04497116
2025-10-21
TRESR
Repare Therapeutics
Phase 1/2
Completed
276 enrolled
33 charts